If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Aptar Pharma and RDD Online co-organize the second edition of RDD ASIA in Goa, India

    Quick Contact
    • Aptar Pharma
    Aptar Pharma and RDD Online co-organize the second edition of RDD ASIA in Goa, India
    Europe, Asia, East Asia, South Asia, India, Health, Pharmaceuticals, Premium, Primary Packaging, Aerosols, Dispensing Closures, Sprays, Pharmaceutical Components, Drug Delivery Devices, Nasal Sprays, Formulations

    Aptar Pharma and RDD Online today announced the second Respiratory Drug Delivery (RDD®) Asia scientific conference which will welcome pulmonary and nasal drug delivery experts from all over the world to Goa, India from November 8-11, 2016. Online registration is available at: http://www.rddonline.com/rddasia2016

    Bringing the respiratory world together in Asia

    Following the success of the first conference in 2014, RDD Asia 2016 will return to Goa, India and will be held at the Grand Hyatt Hotel, November 8-11, 2016.

    RDD Asia 2016 is an extension of the US and European RDD meetings into one of the world’s prominent emerging markets and center for inhalation development and manufacturing.

    RDD Asia 2016 seeks to link industrial and academic scientists, clinicians, regulators, and business professionals in Asia with their international counterparts, to collectively advance inhaled and nasal drug therapy worldwide.

    RDD Asia 2016 presenters will summarize recent developments and offer expert insights designed to energize the audience and spur new thinking and ideas.

    This dynamic environment will serve as a bridge to support academic collaboration, international regulatory harmonization and commercial development across continents. More than 200 delegates from Asia and beyond are expected to attend the conference in Goa.

    Premium scientific symposium in India

    The RDD Asia 2016 scientific conference will feature:

    • Expert speakers addressing a blend of contemporary issues and essential background relating to pMDIs, DPIs, nebulizers, nasal sprays and emerging aerosol delivery platforms.
      Discussions will include different directions for inhaled and nasal drug delivery, fighting Chronic Obstructive Pulmonary Disease, Tuberculosis and respiratory infections, novel in vitro test methods and regulatory science, optimizing DPI formulation and device partnerships and understanding the science of aerosol clouds.
    • Scientific poster session and technology exhibition in which device and equipment designers and component suppliers will present their latest innovations alongside scientific posters from the international aerosol community.
    • Workshop sessions featuring practical and interactive demonstrations of new technologies, products and services.

    RDD Asia 2016 also offers premium formal and informal networking opportunities, including a welcome reception on November 8 and a Gala Dinner sponsored by Aptar Pharma on November 10.

    “We are extremely proud to co-host the latest RDD Asia. The first conference in 2014 received very positive feedback from the audience and was a great success. It put Asia at the center of the inhalation map and for the first time experts met in our backyard. The RDD Asia 2016 scientific conference is a brilliant opportunity to continue discussions and networking on respiratory drug delivery topics that impact Asia and the rest of the world,”said Kanwal Tikoo, Vice President India and South East Asia, Aptar Pharma India.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Company News
    • English
    • Modified 04 Nov 2016
    • Hits 1399
    Sun-Rain
    Epopack
    UNICOA LTD.